A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Trial Profile

A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2013

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms FLUARIX-071
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Aug 2012 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.
    • 04 Aug 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2012-000789-39).
    • 19 Jul 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top